Xcout IntelPersonalis, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Personalis, Inc. among biotech companies — ranked by similarity to what Personalis, Inc. actually does, not by market-cap band.
Subscribe to see Personalis, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Personalis, Inc.
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
Personalis, Inc. at a glance
Personalis, Inc. is a biotech company headquartered in Fremont, United States. It is publicly listed (PSNL) with a market capitalisation of $1.7B. Xcout tracks 17 named people at Personalis, Inc., including Christopher Hall (CEO & Director). Xcout recorded 29 job postings from Personalis, Inc. in the last 90 days, naming tools such as GitHub.
Personalis, Inc. leadership
- Christopher HallCEO & Director
- Richard ChenPresident & Chief Medical Officer
- Aaron L. TachibanaChief Financial Officer & Chief Operating Officer
- Stephen MooreSenior Vice President, Chief Legal Officer & Corporate Secretary
- Ashish KheterpalSenior Vice President & Chief Information Officer
- Euan A. Ashley DPHIL FRCPCo-Founder and Member of Clinical & Scientific Advisory Board
11 more named people on record for Personalis, Inc., with roles, board committees and tenure — see the full roster →
Personalis, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $33M | 2 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Personalis, Inc.
Xcout recorded 29 job postings from Personalis, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
Tools named in Personalis, Inc.'s job postings
The weekly hiring trend, the roles and locations behind it — see Personalis, Inc.'s hiring signals →
Recent Personalis, Inc. news
- AcquisitionM&A communication (425)
- AcquisitionM&A communication (425)
- AcquisitionTempus buys cancer diagnostics firm Personalis for $1.5B
- AcquisitionM&A communication (425)
7 corporate events on record, with sources — see the full timeline →
Top 12 Personalis, Inc. competitors
Ranked by semantic similarity — how close each company is to Personalis, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Medical - Diagnostics & Research
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Biotechnology
Nexome Genomics provides cloud-based, integrated analytics solutions that process next-generation sequencing data for healthcare institutions. The company enables hospitals, medical centers, and physician offices to generate on-demand diagnostic and prognostic reports for precision medicine.
Biotechnology
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Similar biotech company
Cofactor Genomics develops RNA-Seq technology and predictive diagnostics to help match cancer patients with appropriate immunotherapy treatments. The company offers tools such as the OncoPrism assay and collaborates with healthcare systems and clinical researchers to evaluate multidimensional biomarkers for various solid tumor cancers.
Biotechnology
SAGA Diagnostics provides ultra-sensitive, blood-based molecular residual disease (MRD) detection and monitoring tests for cancer patients. The company's flagship platform, Pathlight, uses tumor whole-genome sequencing and personalized digital PCR assays to detect circulating tumor DNA, primarily serving clinicians and biopharmaceutical partners for early cancer detection and treatment tracking.
Similar biotech company
Foundation Medicine, Inc. is an American company based in Boston, Massachusetts, which develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumors, hematologic malignancies, and sarcomas.
Similar biotech company
Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, powered by the proprietary PathFinderTG platform, assists medical professionals in more accurately determining the risk of pancreaticobiliary cancers. It also offers PanDNA, a molecular-only variant of PancraGEN, which delivers insights into a select number of diagnostic markers. For thyroid health, the company provides ThyGeNEXT, an oncogenic mutation panel designed to identify malignant thyroid nodules. Additionally, ThyraMIR evaluates thyroid nodules for malignancy risk through the application of its proprietary microRNA gene-expression assay. Furthermore, RespriDx is a genomic diagnostic tool that aids clinicians in distinguishing between metastatic and recurrent lung cancer. Interpace Biosciences further supports the pharmaceutical and biotechnology sectors with services including pharmacogenomics testing, genotyping, biorepository solutions, and various custom scientific offerings. Its clientele primarily consists of physicians, hospitals, and clinics. Previously operating as Interpace Diagnostics Group, Inc., the company adopted its current name, Interpace Biosciences, Inc., in November 2019. Founded in 1986, its corporate headquarters are located in Parsippany, New Jersey.
Biotechnology
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
Biotech, Diagnostics
Novigenix is an immuno-transcriptomics and TechBio company that provides precision oncology solutions for biopharmaceutical companies and researchers. It offers LITOseek, an AI-powered liquid biopsy platform that analyzes gene activity in immune cells to support biomarker discovery, therapy development, and patient response monitoring.
Similar biotech company
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).
Biotechnology
Predicine Holdings Ltd provides next-generation liquid biopsy platforms and molecular profiling services for cancer research and precision medicine. The company utilizes proprietary blood- and urine-based assays to analyze circulating tumor DNA and RNA, serving biopharmaceutical partners and clinical researchers in oncology drug development and clinical trials.
Similar biotech company
IntegraGen develops genomic tests, molecular diagnostic products, and bioinformatics software for researchers, clinicians, and biopharma companies. The company specializes in oncology and genetic diseases, offering next-generation sequencing services, data analysis tools, and biomarker identification to support clinical research and diagnostics.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Personalis, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Personalis, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →